pocketful logo
Zim Laboratories Ltd logo

Zim Laboratories Ltd

NSE: ZIMLAB BSE: 541400

₹69.75

(-0.98%)

Mon, 02 Mar 2026, 04:50 pm

mtf coin illustrationMTF 5x

Zim Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    372.09

  • Net Profit

    12.17

  • P/B

    1.56

  • Sector P/E

    32.50

  • P/E

    32.08

  • EV/EBITDA

    10.22

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    10.03

  • ROCE (Industry)

    12.82

  • RONW (Industry)

    12.23

  • ROE

    4.96

  • ROCE

    8.16

  • Debt/Equity

    0.47

  • EPS (TTM)

    1.31

  • Dividend Yield

    0

  • Book Value

    53.52

  • Interest Cover

    2.58

Analysis

all

thumbs up icon

Pros

  • Dividends paid are well covered by earnings (4.1x coverage).
  • ZIM Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ZIM Laboratories is profitable, therefore cash runway is not a concern.
  • ZIM Laboratories is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (28.4%, greater than 20% of total debt).
thumbs up icon

Cons

  • ZIM Laboratories has only been paying a dividend for 2 years, and since then there has been no growth.
  • Whilst dividend payments have been stable, ZIM Laboratories has been paying a dividend for less than 10 years.
  • ZIM Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • ZIM Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Interest payments on debt are not well covered by earnings (EBIT is 0.6x annual interest expense, ideally 3x coverage).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters33.2633.2633.2633.2633.26
FII0.0200.030.010.21
DII0.200.240.240.240.24
Public66.5266.5166.4666.4966.28
Government00000

Read More

Technical Analysis

RSI

42.05

MACD

-0.98

50 DMA

71.86

200 DMA

82.18

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic96.2784.3877.0672.4965.1760.6048.71
Fibonacci84.3879.8377.0372.4967.9465.1460.60
Camarilla73.0271.9370.8472.4968.6667.5766.48

Pivots Level: Classic

R3

+23.78

96.27

R2

+11.89

84.38

R1

+4.58

77.06

72.49
72.49
Pivot Point
LTP: 68.48

S1

-7.31

65.17

S2

-11.89

60.60

S3

-23.78

48.71

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    70.03

  • 20-EMA

    70.97

  • 30-EMA

    71.40

  • 50-EMA

    71.86

  • 100-EMA

    73.87

  • 200-EMA

    79.54

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
11 Feb 2026board-meetingsQuarterly Results, Half Yearly Results
21 Jan 2026egm
03 Jun 2025agm
06 Jun 2024agm
20 May 2024agmAnnual General Meeting21 Jun 2024
15 Jun 2023agm
03 Jun 2023agmAnnual General Meeting04 Jul 2023
12 Dec 2022bonus2:1 Bonus Issue of Equity Shares22 Dec 2022
22 Nov 2022bonusBonus issue 2:122 Dec 2022
12 Nov 2022egm

Read More

Peer Comparison

Zim Laboratories Ltd logo

Zim Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Zim Laboratories Ltd About

Zim Laboratories is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1984

Headquarters

CEO

Anwar S Daud

Employees

Contact

Website icon

Website

http://www.zimlab.in

Email icon

Email

cs@zimlab.in

Phone icon

Phone

91-712-2588070

Location icon

Location

Sadoday Gyan (Gr Floor), Opp NADT Nelson Square, Nagpur, Maharashtra, 440013

Read More

Zim Laboratories Ltd Company History

YearHistory
1992
  • The company became a Public Ltd. Company by passing special resolution dated 25th January.
1993
  • The company obtained a fresh certificate of incorporation from Registrar of Companies, Maharashtra Bombay, on 21st January.
2018
  • The Company has issued Bonus Shares in the Ratio of 1:1.
2022
  • The Company has issued Bonus Shares in the Ratio of 2:1.
  • Company received Global Nagpur Awards in December.
2023
  • Company Received Excellence In Pharma Global Business in April.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
ELIZABETH MATHEWSell384000073.4511 Nov 2025
ELIMATH ADVISORS PRIVATE LIMITEDBuy384000073.4711 Nov 2025
AJIT RAMKARAN SARDASell14289282.0229 Oct 2025
AJIT RAMKARAN SARDABuy26548381.5829 Oct 2025
ELIMATH ADVISORS PRIVATE LIMITEDBuy149712468.7924 Oct 2025
MATHEW CYRIACSell156900068.8424 Oct 2025
ELIZABETH MATHEWSell1794000115.3117 Jul 2025
MATHEW CYRIACBuy1794000115.3117 Jul 2025
YUGA STOCKS AND COMMODITIES PRIVATE LIMITEDBuy4185999.7320 Mar 2025
YUGA STOCKS AND COMMODITIES PRIVATE LIMITEDSell47732193.5120 Mar 2025

Read More

Zim Laboratories Ltd News

ZIM Labs Gets DMCC Approval for Subsidiary Closure

ZIM Laboratories receives Dubai Multi Commodities Centre Authority approval for closure of step-down subsidiary ZIM DMCC with effect from February 23, 2026, following earlier board approval in August 2025.

23 Feb 2026

stocks

ZIM Labs Gets Credit Rating Reaffirmation from ACUITE

ZIM Laboratories receives reaffirmed credit ratings from ACUITE Ratings with BBB stable rating for long-term facilities worth Rs. 150.23 crores and A3+ rating for short-term facilities of Rs. 16.00 crores.

17 Feb 2026

stocks

ZIM Laboratories Receives GST Demand of Rs. 2.19 Cr

ZIM Laboratories disclosed receipt of GST demand notice worth Rs. 2,19,64,841 from Maharashtra tax authorities for FY 2021-22, alleging excess input tax credit availed. Company plans to file appeal.

11 Feb 2026

stocks

ZIM Laboratories Q3FY26 Revenue Jumps 12.8% to ₹1,087 Mn

ZIM Laboratories reported strong Q3FY26 performance with total operating income rising 12.8% YoY to ₹1,087 Mn. EBITDA grew 9.1% to ₹145 Mn while PAT increased 9.9% to ₹44 Mn, marking recovery from previous quarter losses.

11 Feb 2026

co actions results

ZIM Labs Appoints New President, Elevates Two VPs

ZIM Laboratories appointed Vikrant Bendre as President-International Business and categorized two Vice Presidents as Senior Management Personnel effective February 2, 2026.

02 Feb 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800